At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
Ipilimumab +1 moredrug
Likely dose
Ipilimumab 3 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of Ipilimumab in Subjects With Stage IV Melanoma Receiving Palliative Radiation Therapy
In Brief
A Phase 2 clinical trial evaluating Ipilimumab and Radiation Therapy for Melanoma. Completed, enrolled 22 participants across 1 site.
Detailed Summary
To determine the safety of local palliative radiation therapy used in combination with anti-CTLA-4 immunotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2011
First PostedOct 2011
Primary CompletionDec 2015
Study CompletionDec 2016
TodayJul 2026
First PostedOct 10, 2011
Enrollment StartOct 1, 2011
Primary CompletionDec 31, 2015
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 14.7 years ago
Interventions
Ipilimumabdrug
Ipilimumab will be administered as a single agent standard of care with base dose of 3 mg/kg iv over approximately 90 minutes every 3 weeks for a total of 4 treatments.
Radiation Therapyradiation
Standard of care palliative radiation therapy will start within 5 days of the first ipilimumab dose. Dose is dependent upon lesion size and is determined by the radiation oncologist.